Stay updated on KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial

Sign up to get notified when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page

  1. Check
    7 days ago
    Change Detected
    Summary
    Enrollment status updated to Completed on 2026-05-11, replacing the prior Active, not recruiting status. This signals that the study has finished enrolling participants and is moving toward completion and results submission.
    Difference
    0.1%
    Check dated 2026-05-14T07:47:07.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Added a Tampa, Florida site (33614-2846) with status Completed. Removed a Tampa site (33614-2869) that was Active, not recruiting, reflecting a change in recruitment status at that location.
    Difference
    0.1%
    Check dated 2026-05-07T09:15:19.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    This update expands the number of locations from 119 to 154 by adding numerous sites across multiple countries, including the UK, Switzerland, Poland, Peru, Chile, China, and more. It reflects a broader recruitment footprint across the study network.
    Difference
    8%
    Check dated 2026-04-30T02:41:05.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    The study record was updated with new date/version information and a location change in Florida (adding/reflecting a Stuart, FL site while an earlier Okeechobee, FL listing was removed). A revision/version label also changed (from v3.5.0 to v3.5.2).
    Difference
    0.3%
    Check dated 2026-04-22T17:49:59.000Z thumbnail image
  5. Check
    50 days ago
    Change Detected
    Summary
    Sponsor name updated from Karuna Therapeutics to Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
    Difference
    0.1%
    Check dated 2026-04-01T02:58:41.000Z thumbnail image
  6. Check
    57 days ago
    Change Detected
    Summary
    Additions include new study identifiers, IPD sharing details, expanded inclusion criteria (MRI/CT within 5 years, age 55-90, study partner), and new endpoints (NPI-C H+D, CGI-S, responder rate) as well as the Placebo arm and numerous global sites. Deletions remove CMAI-related outcome information (CMAI score and its description).
    Difference
    1%
    Check dated 2026-03-24T21:28:23.000Z thumbnail image

Stay in the know with updates to KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KarXT for Alzheimer's Psychosis: ADEPT-2 Clinical Trial page.